Cingulate Inc. (CING) Investor Relations Documents

Cingulate Inc. (CING) investor relations documents from the company's IR site: 1 presentation, 9 press releases; latest deck 2021-01-15. Read in-app with summaries. First-party data.

2021 APSARD Poster: A crossover study of CTx-1301 versus Focalin XR in 45 ADHD adults shows a 16-hour duration of action and a 28.6% reduction in drug-related adverse events.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13Press releaseCingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Re
2026-08-11Press releaseCingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
2026-07-30Press releaseCingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
2026-07-02Press releaseCingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
2026-06-16Press releaseCingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
2026-06-02Press releaseCingulate Receives Complete Response Letter from FDA for CTx-1301
2026-05-14Press releaseCingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Tr
2026-03-18Press releaseCingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
2026-02-17Press releaseCingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2021-01-15Presentation2021 APSARD Poster

CING overview · CING earnings · CING financials · CING KPIs · CING ownership · CING peers · CING filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.